In a subset of metastatic gastrinoma patients treated with 90Y and/or 177Lu-based therapies, studies reported reductions in serum gastrin levels by up to 81%, along with tumor response in over 50% of cases. This evidence concerns the gene GAST and gastrin-producing neuroendocrine tumor.